Genzyme Articles
Dyax start Ph III trials of angiodema drug
19 December 2005
Genzyme's UGT1A1 assay launched onto oncology market
12 December 2005
Genzyme's Campath for MS subject of FDA health warning
12 December 2005
CAT's fiscal year results beat forecasts
5 December 2005
CORRECTION: Genzyme
22 August 2005
Stock Commentary - New York
8 August 2005
Genzyyme submits BLA for Myozyme
8 August 2005
Lower death rate with long-term Renegal
8 August 2005
Stock Commentary - New York
25 July 2005
Genzyme guidance upped on good 2nd qtr
25 July 2005
Genzyme concludes Bone Care purchase
11 July 2005
Dyax changes DX-88 to subcutaneous form
11 July 2005
Progress in Genzyme's buy of Bone Care Int
20 June 2005
Stock Commentary - New York
16 May 2005
BCI advances LR-103 into kidney disease trial
16 May 2005
Genzyme to buy Bone Care for $600M
16 May 2005
Genzyme's 1st-qtr revenues up 28%
25 April 2005
Senior appointments at Synta Pharma
18 April 2005
Dyax to explore subcutaneous route for DX-88
4 April 2005
CAT abandons Trabio after second clinical trial failure
28 March 2005
Appointments at Encysive
28 March 2005
Stock Commentary - New York
14 March 2005
EC OKs new use for Genzyme's Thyrogen
14 March 2005
Genzyme $57.3M net loss for 4th qtr 2004
28 February 2005
Genzyme acquires Germany's Verigen
14 February 2005
Stock Commentary - New York
24 January 2005
Highlights of pharmaceutical mergers and acquisitions in 2004
24 January 2005
Appointments at Enzon Pharma
17 January 2005
Genzyme completes buyback of Synvisc
17 January 2005
Positive data for Dyax' angioedema drug
17 January 2005
Stock Commentary - Europe
10 January 2005
Genzyme completes ILEX Oncology buy
10 January 2005
Myzozyme MAA lifts Genzyme
10 January 2005
Positive results for Dyax/Genzyme's DX-88
22 November 2004
Nabi files for approval of PhosLo in EU
15 November 2004
Genzyme swings to profit in 3rd qtr
1 November 2004
Clinical benefits of Fabrazyme confirmed
27 September 2004
Valentis and Genzyme extend GeneSwitch agreement
13 September 2004
BioMarin sees 2nd-qtr loss rocket on Ascent acquisition
16 August 2004
Stock Commentary - New York
26 July 2004
UPDATE: Shire's Fosrenol faces delay for US approval
26 July 2004
Genzyme's 2nd-qtr revenues jump 58%
19 July 2004
Dyax/Genzyme's DX-88 succeeds in Ph II trial
21 June 2004
Medtronic and Genzyme set up JV
14 June 2004
Dyax and Genzyme in antibody deal
7 June 2004
Dyax shares plunge as FDA puts hold on trial
31 May 2004
Genzyme posts 1st-qtr net income of $67.9M
26 April 2004
Genzyme grants P&G exclusive RDP58 licence
12 April 2004
UK judicial decison impacts Genzyme
22 March 2004
Stock Commentary - New York
8 March 2004
Genzyme to buy ILEX for $1 billion
8 March 2004
CAT-192 is safe but efficacy in doubt
16 February 2004
TKT's Replagal cleared in Canada
16 February 2004
New Chemical Entities in 2003
19 January 2004
Genzyme to set up research facility in UK
19 January 2004
TKT will not seek US OK for Replagal
19 January 2004
Genzyme's revenues growth solid in 2003
30 November 2003
FTC closes review of Genzyme's Novazyme buy
30 November 2003
Genzyme starts Ph I trial for MS therapy
22 December 2003
Stock Commentary - New York
15 December 2003
Genzyme closes sale of convertible notes
15 December 2003
CAT takes Abbott to court over Humira
24 November 2003
Genzyme swings to loss on acquisition costs
27 October 2003
TKT and Genzyme sign deal for I2S
27 October 2003
Irish Deputy Premier to attend CORDIA
6 October 2003
CAT and Genzyme amend collaboration
29 September 2003
Genzyme completes $600M SangStat deal
22 September 2003
EC OKs new use for Genzyme's Cerezyme
22 September 2003
Genzyme files Synvisc in Japan
15 September 2003
Genzyme receives rare boost in 2nd qtr
21 July 2003
Tokyo pharma stocks - week to July 7
14 July 2003
Stock Commentary - Tokyo
14 July 2003
Italy seeks US aid over Pompe disease
30 June 2003
Cerezyme closer to expanded use in EU
23 June 2003
EU clears Genzyme, BioMarin drug for MPS
23 June 2003
Genzyme therapy in Niemann-Pick disease
16 June 2003
Genzyme's Myozyme begins Pompe study
9 June 2003
Shareholders file lawsuit against Genzyme
9 June 2003
US orphan drug costs "up 40% per year"
9 June 2003
SEC investigates TKT's Replagal disclosures
26 May 2003
Stock Commentary - New York
19 May 2003
FDA clears Genzyme, BioMarin drug for MPS
12 May 2003
Stock Commentary - New York
5 May 2003
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
